Navigation Links
FDA Approves New Treatment for Chronic Hepatitis B

The Food and Drug Administration (FDA) announced the approval of Baraclude (entecavir) tablets and oral solution for the treatment of chronic hepatitis B in adults. Chronic hepatitis B is a serious disease caused by the hepatitis B virus (HBV) that attacks the liver. The virus can cause lifelong infection, cirrhosis (scarring) of the liver, liver cancer, liver failure, and death. According to the Centers for Disease Control and Prevention, approximately 1.25 million Americans are chronically infected with the HBV virus.

Baraclude slows the progression of chronic hepatitis B by interfering with viral reproduction.

FDA based its approval of Baraclude on the results of three studies in which Baraclude was compared to another anti-viral drug, lamivudine.

In all three clinical studies, patients treated with Baraclude showed significant improvement in the liver inflammation caused by HBV and an improvement in the degree of liver fibrosis (scarring). In addition, a higher percentage of patients treated with Baraclude showed significant improvement compared to lamivudine.

The major adverse events associated with the use of Baraclude were of the type typically seen with HBV therapy. They include severe, acute exacerbation of hepatitis B after discontinuation of Baraclude, headache, abdominal pain, diarrhea, fatigue, and dizziness. The labeling for Baraclude states that patients who discontinue Baraclude should be monitored at repeated intervals over a period of time for liver function.

Baraclude's sponsor, Bristol-Myers Squibb Company of Wallingford, Conn., has committed to conducting a large post-marketing study of Baraclude (entecavir) to evaluate the risks of cancers and liver related complications.


'"/>

Source:U.S. FDA


Page: 1

Related biology news :

1. FDA Approves Human Hookworm Vaccine for Phase I Safety Trials
2. FDA Approves New Drug to Treat Type I and Type II Diabetes
3. Discovery Could Lead To Novel Approaches In HIV Treatment
4. New Treatment Rivals Chemotherapy For Lymphoma, Study Finds
5. Rush Physicians Using Gene Therapy For Heart Patients With Moderate To Severe Chest Pains Who Do Not Benefit From Other Treatments
6. Effective Cancer Treatments Follow The Clock
7. Protein Discovery Could Unlock The Secret To Better TB Treatment
8. Natural Killers Could Lead to New Hepatitis Treatments
9. Study Finds Moderate Hypothermia A Safe Treatment For Traumatic Brain Injury In Kids
10. Drug Offers Alternative to Surgical Treatment After Miscarriage
11. Treatments have same target, different responses for lung cancer patients with genetic mutation
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/2/2017)... Who risk to be deprived of its ... report: https://www.reportbuyer.com/product/4313699/ WILL APPLE AND SAMSUNG ... Fingerprint sensors using capacitive technology represent a fast growing ... forecasts an increase of 360% of the number of ... fingerprint sensor market between 2014 and 2017 (source : ...
(Date:3/1/2017)... 2017  Aware, Inc. (NASDAQ: AWRE), a leading supplier ... P. Moberg has resigned, effective March 3, 2017, ... Officer and Treasurer of Aware citing a desire to ... member of the Board of Directors of Aware. ... Officer and co-President, General Counsel has been named Chief ...
(Date:2/28/2017)... February 28, 2017 News solutions for biometrics, ... ... from 14 to 16 March, Materna will present its ... how seamless travel is a real benefit for passengers. To ... to their passenger touch point solutions to take passengers through the ...
Breaking Biology News(10 mins):
(Date:3/22/2017)... , March 22, 2017 /PRNewswire/ - FACIT announced ... "Company" or "Propellon"), a start-up created by FACIT ... therapeutics. FACIT,s investment, combined with non-dilutive capital, achieves ... The seed funding enables Propellon to accelerate the ... Company for financing and/or entering a strategic partnership ...
(Date:3/22/2017)... ... ... executive recruitment firm, Slone Partners, is proud to have been named a Top 50 ... Scanlon Media is one of the most respected life science publications in the United ... , “It is a great honor for Slone Partners to be part of this ...
(Date:3/22/2017)... ... March 21, 2017 , ... Benchworks CEO ... Executive Officer Forum on March 23-24 in San Diego. The event is a ... diagnostic industries. , Benchworks Vice President Christian Meyer will also participate in the ...
(Date:3/22/2017)... ... March 21, 2017 , ... ... has unveiled its innovative Quantum peristaltic pump with patented ReNu single-use (SU) ... the new standard for high-pressure feed pumps in SU tangential flow filtration ...
Breaking Biology Technology: